These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

202 related articles for article (PubMed ID: 23981511)

  • 21. Side effects of minocycline treatment in patients with fragile X syndrome and exploration of outcome measures.
    Utari A; Chonchaiya W; Rivera SM; Schneider A; Hagerman RJ; Faradz SM; Ethell IM; Nguyen DV
    Am J Intellect Dev Disabil; 2010 Sep; 115(5):433-43. PubMed ID: 20687826
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Auditory repetition suppression alterations in relation to cognitive functioning in fragile X syndrome: a combined EEG and machine learning approach.
    Knoth IS; Lajnef T; Rigoulot S; Lacourse K; Vannasing P; Michaud JL; Jacquemont S; Major P; Jerbi K; Lippé S
    J Neurodev Disord; 2018 Jan; 10(1):4. PubMed ID: 29378522
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Auditory change detection in fragile X syndrome males: a brain potential study.
    Van der Molen MJ; Van der Molen MW; Ridderinkhof KR; Hamel BC; Curfs LM; Ramakers GJ
    Clin Neurophysiol; 2012 Jul; 123(7):1309-18. PubMed ID: 22192499
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Auditory EEG Biomarkers in Fragile X Syndrome: Clinical Relevance.
    Ethridge LE; De Stefano LA; Schmitt LM; Woodruff NE; Brown KL; Tran M; Wang J; Pedapati EV; Erickson CA; Sweeney JA
    Front Integr Neurosci; 2019; 13():60. PubMed ID: 31649514
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Developmental Changes in EEG Phenotypes in a Mouse Model of Fragile X Syndrome.
    Wen TH; Lovelace JW; Ethell IM; Binder DK; Razak KA
    Neuroscience; 2019 Feb; 398():126-143. PubMed ID: 30528856
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Neural synchronization deficits linked to cortical hyper-excitability and auditory hypersensitivity in fragile X syndrome.
    Ethridge LE; White SP; Mosconi MW; Wang J; Pedapati EV; Erickson CA; Byerly MJ; Sweeney JA
    Mol Autism; 2017; 8():22. PubMed ID: 28596820
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Brain regions activated during an auditory discrimination task in insomniac postmenopausal patients before and after hormone replacement therapy: low-resolution brain electromagnetic tomography applied to event-related potentials.
    Anderer P; Saletu B; Saletu-Zyhlarz G; Gruber D; Metka M; Huber J; Pascual-Marqui RD
    Neuropsychobiology; 2004; 49(3):134-53. PubMed ID: 15034229
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A phase 1, randomized double-blind, placebo controlled trial to evaluate safety and efficacy of epigallocatechin-3-gallate and cognitive training in adults with Fragile X syndrome.
    de la Torre R; de Sola S; Farré M; Xicota L; Cuenca-Royo A; Rodriguez J; León A; Langohr K; Gomis-González M; Hernandez G; Esteba S; Del Hoyo L; Sánchez-Gutiérrez J; Cortés MJ; Ozaita A; Espadaler JM; Novell R; Martínez-Leal R; Milá M; Dierssen M;
    Clin Nutr; 2020 Feb; 39(2):378-387. PubMed ID: 30962103
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Auditory evoked magnetic fields in adults with fragile X syndrome.
    Rojas DC; Benkers TL; Rogers SJ; Teale PD; Reite ML; Hagerman RJ
    Neuroreport; 2001 Aug; 12(11):2573-6. PubMed ID: 11496151
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Mavoglurant in fragile X syndrome: Results of two randomized, double-blind, placebo-controlled trials.
    Berry-Kravis E; Des Portes V; Hagerman R; Jacquemont S; Charles P; Visootsak J; Brinkman M; Rerat K; Koumaras B; Zhu L; Barth GM; Jaecklin T; Apostol G; von Raison F
    Sci Transl Med; 2016 Jan; 8(321):321ra5. PubMed ID: 26764156
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Mechanism-based treatments in neurodevelopmental disorders: fragile X syndrome.
    Berry-Kravis E
    Pediatr Neurol; 2014 Apr; 50(4):297-302. PubMed ID: 24518745
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Enhanced Excitatory Connectivity and Disturbed Sound Processing in the Auditory Brainstem of Fragile X Mice.
    Garcia-Pino E; Gessele N; Koch U
    J Neurosci; 2017 Aug; 37(31):7403-7419. PubMed ID: 28674175
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Combining Lovastatin and Minocycline for the Treatment of Fragile X Syndrome: Results From the LovaMiX Clinical Trial.
    Champigny C; Morin-Parent F; Bellehumeur-Lefebvre L; Çaku A; Lepage JF; Corbin F
    Front Psychiatry; 2021; 12():762967. PubMed ID: 35058813
    [No Abstract]   [Full Text] [Related]  

  • 34. Effects of hormone replacement therapy on perceptual and cognitive event-related potentials in menopausal insomnia.
    Anderer P; Semlitsch HV; Saletu B; Saletu-Zyhlarz G; Gruber D; Metka M; Huber J; Gräser T; Oettel M
    Psychoneuroendocrinology; 2003 Apr; 28(3):419-45. PubMed ID: 12573306
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Effect of CX516, an AMPA-modulating compound, on cognition and behavior in fragile X syndrome: a controlled trial.
    Berry-Kravis E; Krause SE; Block SS; Guter S; Wuu J; Leurgans S; Decle P; Potanos K; Cook E; Salt J; Maino D; Weinberg D; Lara R; Jardini T; Cogswell J; Johnson SA; Hagerman R
    J Child Adolesc Psychopharmacol; 2006 Oct; 16(5):525-40. PubMed ID: 17069542
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Beneficial effects of sound exposure on auditory cortex development in a mouse model of Fragile X Syndrome.
    Kulinich AO; Reinhard SM; Rais M; Lovelace JW; Scott V; Binder DK; Razak KA; Ethell IM
    Neurobiol Dis; 2020 Feb; 134():104622. PubMed ID: 31698054
    [TBL] [Abstract][Full Text] [Related]  

  • 37. EEG as a translational biomarker and outcome measure in fragile X syndrome.
    Kenny A; Wright D; Stanfield AC
    Transl Psychiatry; 2022 Jan; 12(1):34. PubMed ID: 35075104
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The effects of immediate and short-term retest on the latencies and amplitudes of the auditory event-related potentials in healthy adults.
    Gandelman-Marton R; Theitler J; Klein C; Rabey JM
    J Neurosci Methods; 2010 Jan; 186(1):77-80. PubMed ID: 19854216
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Effect of the mGluR5-NAM Basimglurant on Behavior in Adolescents and Adults with Fragile X Syndrome in a Randomized, Double-Blind, Placebo-Controlled Trial: FragXis Phase 2 Results.
    Youssef EA; Berry-Kravis E; Czech C; Hagerman RJ; Hessl D; Wong CY; Rabbia M; Deptula D; John A; Kinch R; Drewitt P; Lindemann L; Marcinowski M; Langland R; Horn C; Fontoura P; Santarelli L; Quiroz JA;
    Neuropsychopharmacology; 2018 Feb; 43(3):503-512. PubMed ID: 28816242
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Impact of acamprosate on behavior and brain-derived neurotrophic factor: an open-label study in youth with fragile X syndrome.
    Erickson CA; Wink LK; Ray B; Early MC; Stiegelmeyer E; Mathieu-Frasier L; Patrick V; Lahiri DK; McDougle CJ
    Psychopharmacology (Berl); 2013 Jul; 228(1):75-84. PubMed ID: 23436129
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.